This article is more than 5 years old. Information may no longer be current.

VIDEO: Mogamulizumab ‘promising’ therapy for patients with rare ATL

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A humanized monoclonal antibody directed against C-C chemokine receptor 4 effectively treated patients with adult T-cell leukemia/lymphoma when compared with standard chemotherapy, according to research Adrienne A. Phillips, MD, MPH, of Weill Cornell Medicine and NewYork-Presbyterian, presented at the ASCO Annual Meeting.

Phillips and colleagues conducted a randomized study in which patients either received mogamulizumab (Poteligeo, Kyowa Kirin Pharmaceutical Development) or a standard chemotherapy treatment of either pralatrexate (Folotyn, Spectrum Pharmaceuticals), DHAP or gemcitabine-oxaliplatin.

The response rate in patients who received mogamulizumab was 34% compared with no response in patients who received chemotherapy.

“Mogamulizumab... is promising for patients with ATL who otherwise have had no standard options [in the U.S.], Phillips said. “[Also], chemotherapy in the relapsed refractory setting is ineffective.”